Qingdao Baheal Medical INC. (SHE:301015)

SHE:301015 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022
Revenue Revenue Growth	7,449	7,507	8,094	8,256	7,510	7,052
Revenue Growth	-7.89%	-7.26%	-1.96%	9.94%	6.50%	19.94%
Gross Profit Gross Profit Growth	2,811	2,766	2,866	2,751	2,084	1,774
Operating Income Operating Income Growth	717.75	723.41	981.91	1,053	712.6	614.75
Net Income Net Income Growth	513.61	474.69	691.59	712.06	502.09	421.64
Earnings Per Share EPS Growth	0.96	0.89	1.28	1.33	0.96	0.85
EPS Growth	-12.85%	-30.47%	-3.76%	38.54%	12.94%	46.55%

Revenue by Segment

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022
Brand Operation Business Segment Brand Operation Business Segment Growth	5,624	5,559	5,092	3,700	2,905
Pharmaceutical Wholesale and Distribution Business Division Pharmaceutical Wholesale and Distribution Business Division Growth	1,458	2,136	2,774	3,434	3,706
Retail Business Segment Retail Business Segment Growth	397.66	373.3	360.02	359.71	418.6
Unallocated Other Operating Income Unallocated Other Operating Income Growth	26.67	26.03	29.96	15.19	22
Total Total Growth	7,507	8,094	8,256	7,510	7,052

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022
Cash & Investments Cash & Investments Growth	2,743	2,402	1,512	1,372	1,075	1,317
Total Debt Total Debt Growth	3,814	3,380	2,385	1,455	1,338	1,226
Net Cash (Debt) Net Cash Growth	-1,071	-978.05	-872.59	-82.51	-262.71	90.77
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-2.00	-1.83	-1.61	-0.15	-0.50	0.18

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022
Operating Cash Flow Operating Cash Flow Growth	657.38	934.45	813.85	799.5	305.75	181.3
Capital Expenditures CapEx Growth	-309.23	-288.93	-303.99	-185.49	-105.32	-27.49
Free Cash Flow Free Cash Flow Growth	348.15	645.52	509.86	614.01	200.43	153.81
Free Cash Flow Growth	-40.72%	26.61%	-16.96%	206.34%	30.31%	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022
Gross Margin	37.73%	36.84%	35.41%	33.32%	27.75%	25.16%
Operating Margin	9.63%	9.64%	12.13%	12.75%	9.49%	8.72%
Pretax Margin	10.38%	9.63%	11.94%	12.45%	8.90%	8.02%
Profit Margin	6.89%	6.32%	8.54%	8.63%	6.69%	5.98%
FCF Margin	4.67%	8.60%	6.30%	7.44%	2.67%	2.18%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 1, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022
Dividend Per Share Dividend Per Share Growth	0.571	0.571	0.762	-	0.762	0.667
Dividend Per Share Growth	-25.07%	-25.07%	-	-	14.24%	-
Dividend Yield	2.55%	2.48%	3.37%	-	3.60%	2.56%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 1, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022
PE Ratio	23.29	26.13	18.40	26.44	24.93	37.74
Forward PE	21.70	16.50	13.27	25.05	21.53	33.48
P/FCF Ratio	33.74	19.22	24.96	30.67	62.46	103.45
PS Ratio	1.58	1.65	1.57	2.28	1.67	2.26

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 1, 2026

Data Sources Report a data error